JPRN-UMIN000040187尚未招募2 期
dose-dense AC or EC therapy followed by dose-dense Paclitaxel as neoadjuvant chemotherapy for triple negative operable breast cancer - PerSeUS-BC05
Gifu University Graduate School of Medicine Department of Surgical Oncology0 个研究点目标入组 35 人开始时间: 2020年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)inflammamatory and/or bilateral breast cancer 2)Duplicated/sunchromus/metachromus cancer(DFS less than 5y) 3)Severe complication(cardiovascular, lung, liver disease, homorragic ulcer etc.) 4)febrile, suspicious for infection 5)Intedstitial pneumonia oe pulmonary fibrosis by chest-X/CT 6)Active systhemic infection()HBV,HCV,HIC etc.) 7)Severe allergy to drug 8)Pregnancy,Lactation 9)Uncontrollable mental disease 10)Not suitable for thes study judged by physician/Surgeon
研究者
相似试验
已完成
2 期
Feasibility Phase 2 study of Dose-dense AC or EC followed by PTX for operable breast cancerbreast cancerJPRN-UMIN000022097PO Setouchi Breast Project50
进行中（未招募）
不适用
Stereotactic body radiotherapy for the treatment of OPDung cancerCancerLung cancerISRCTN53398136Institute of Cancer Research110
尚未招募
3 期
Chemoradiotherapy versus Radiotherapy alone in post-operative locally advanced oral cavity cancerCTRI/2024/06/069157Department Of Radiotherapy and Radiation medicine
已完成
2 期
2nd Nordic Mantle-Cell Lymphoma protocolMantle cell lymphomaCancerLymphomaISRCTN87866680Individual sponsor (Denmark)50
已完成
2 期
Phase 2 study of dose dense AC and dose dense PTX as perioperative chemotherapy for patients with HER2 negative breast cancer(WJOG9016B)HER2 negative breast cancerJPRN-UMIN000024992West Japan Oncology Group90